Relay Therapeutics (RLAY) Cash from Financing Activities (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Cash from Financing Activities data on file, last reported at $138.8 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities changed N/A year-over-year to $138.8 million in Q1 2026; TTM through Mar 2026 was $140.5 million, a N/A change from a year earlier, with the FY2025 full-year figure at $1.6 million, down 99.41% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $138.8 million, up from $934000.0 in the prior quarter.
• Over the last five years, Cash from Financing Activities for RLAY reached as high as $285.9 million in Q3 2022 and fell as low as $17000.0 in Q3 2025.
• Historically, Cash from Financing Activities has averaged $49.0 million across 5 years, with a median of $2.0 million in 2022.
• Across the five-year window, Cash from Financing Activities surged 31592.35% in 2022 and tumbled 99.99% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at $1.2 million in 2022, then soared by 1779.76% to $21.9 million in 2023, then tumbled by 96.35% to $800000.0 in 2024, then climbed by 16.75% to $934000.0 in 2025, then surged by 14758.89% to $138.8 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $138.8 million in Q1 2026, $934000.0 in Q4 2025, and $17000.0 in Q3 2025.